PIKA recombinant COVID-2019 vaccine (LakeShore Biopharma)

皮卡重组蛋白新型冠状病毒疫苗 (LakeShore Biopharma)

Report date: 2024/06/07 12:05:40

Base Information

Drug NamePIKA recombinant COVID-2019 vaccine (LakeShore Biopharma)
Drug Alias NamePIKA recombinant COVID-19 vaccineYS-SC2-010
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPhilippinesUnited Arab EmiratesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesLakeShore Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLakeShore Biopharma Co LtdYisheng Biopharma (Singapore) Pte Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A